SIMCERE PHARMA (02096): Sebexen (Edaravone Solution for Injection) included in the 2026 edition of the National Essential Medicines List.
Sinopharm Holdings (02096) announced that on July 9, 2026, the Group's independently developed innovative drug Sibixin (idaravon mesylate injection concentrate) has been officially included in the "National Essential Medicines List (2026 Edition)" for the treatment of acute ischemic stroke (AIS). According to the relevant management regulations for essential medicines, public medical institutions at all levels nationwide must equip and prioritize the use of drugs listed in the directory. This selection is beneficial for Sibixin to break through the limitations of the original tertiary hospitals, accelerate penetration into county-level and grassroots medical markets, expand terminal prescription scenes, complement existing medical insurance qualifications, further improve drug accessibility, and consolidate the Group's competitive advantage in the field of acute stroke treatment.
SIMCERE PHARMA (02096) announced that on July 9, 2026, the Group's independently developed innovative drug Xian Bi Xin (Edaravone for Injection Concentrate) was officially included in the "National Essential Medicines List (2026 Edition)" for the treatment of acute ischemic stroke (AIS). According to the relevant regulations of essential medicines, public medical institutions at all levels nationwide must equip and prioritize the use of drugs within the list. This selection is beneficial for Xian Bi Xin to break through the limitations of tertiary hospitals, accelerate expansion into county-level and grassroots medical markets, broaden the terminal prescription scene, enhance existing medical insurance qualifications, further improve drug accessibility, and consolidate the Group's competitive advantage in the field of acute ischemic stroke treatment.
Related Articles
On July 9th, ANTON OILFIELD (03337) spent approximately HK$2.9737 million to repurchase 3.63 million shares.
United Asia Pharmaceuticals' GEM IPO has passed review, and 12 products including sustained-release metoprolol succinate tablets have been approved by NMPA for listing and sales.
On July 9, Nayuki (02150) spent approximately HKD 825,700 to repurchase 1.2225 million shares.
On July 9th, ANTON OILFIELD (03337) spent approximately HK$2.9737 million to repurchase 3.63 million shares.
United Asia Pharmaceuticals' GEM IPO has passed review, and 12 products including sustained-release metoprolol succinate tablets have been approved by NMPA for listing and sales.
On July 9, Nayuki (02150) spent approximately HKD 825,700 to repurchase 1.2225 million shares.
RECOMMEND
